1. ALLA AKTIER
  2. NYHETER
  3. ZICCUM

Ziccum

Nyheter Ziccum Nyheter alla bolag

Ziccum announces trademarking LaminarPace in the USA

Ziccum is pleased to announce that the appellation of its proprietary technology, LaminarPace, has been officially registered with the United States Patent and Trademark Office (USPTO) as a trademark since 23 July 2024. Obtaining trademark protection in the US, a market of primary importance to Ziccum, is a significant step in light of Ziccum’s growing industry presence, recognition as a commercial partner of choice, and Ziccum’s continuous scientific progress.

In addition to trademarking LaminarPace the company also received trademark registration for the company name Ziccum by USPTO. The trademarks are valid for 10 years from the priority date associated with the filing of the trademark applications with the USPTO (10 November 2022), and they can then be renewed.

Ziccum applied in 2022 for trademark protection in all the relevant geographical territories for pharmaceutical markets to ensure full protection for the LaminarPace and Ziccum names. The US approval is the first registration obtained.

Ann Gidner, CEO: “As we are gaining growing industrial recognition in the international pharmaceutical industry, it is important to protect the LaminarPace and Ziccum names and their increasing brand value. We are happy to get the formal registration completed for the United States and look forward to receiving further territory approvals ahead”.

For more information about Ziccum, please contact:

Ann Gidner
CEO, Ziccum AB
Mail: gidner@ziccum.com
Mobile: +46 722140141

Jonas Ekblom
Chairman of the Board, Ziccum AB
Mail: ekblom@ziccum.com
Mobile: +46 736777540

Ziccum’s Certified Adviser is
Carnegie Investment Bank AB (publ)
Follow us on https://eucaps.com/ziccum

About Ziccum

Ziccum is developing LaminarPaceTM, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

Ziccum announces trademarking LaminarPace in the USA

Datum 2024-09-16, kl 08:30
Källa MFN
Bifogade filer
Ziccum announces trademarking LaminarPace in the USA
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!